Enzymatica
3.53 SEK +2.62%Be the first to follow this company
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Revenue
50.9M
EBIT %
-94.42 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ENZY
Daily low / high price
3.35 / 3.53
SEK
Market cap
612.04M SEK
Turnover
42.36K SEK
Volume
13K
Financial calendar
Interim report
2024-04-25
General meeting
2024-05-07
Interim report
2024-07-18
Interim report
2024-11-07
Annual report
2025-02-18
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mats Andersson, privat och genom bolag | 22.2 % | 22.2 % |
Roosgruppen AB | 13.6 % | 13.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Enzymatica AB: Enzymatica publicerar årsredovisning för 2023
Notice of Annual General Meeting 2024 in Enzymatica AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools